McKesson — Aug 6, 2025 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000927653-25-000105
Showing in the filing
Quarterly dividend
“$0.82 per share”
Period
No period stated
Measure
Declared action
Source
Prose
All guidance in this release · 5
Quarterly dividend
“$0.82 per share”
Adjusted Earnings per Diluted Share growth v… for FY2026
“12% to 15%”
Adjusted EPS growth excluding fiscal 2025 ne… for FY2026
“14% to 17%”
Adjusted Earnings per Diluted Share for FY2026
“$37.10 to $37.90”
Adjusted Earnings per Diluted Share accretio… for FY2026
“approximately $0.20”
Exhibit 99.1 · the passage around this item
… earlier in the release
• Adjusted Earnings per Diluted Share of $8.26 increased 5%. • McKesson completed the transactions to acquire controlling interests in PRISM Vision Holdings, LLC and Core Ventures. • McKesson's Board of Directors approved a 15% increase to the quarterly dividend, to $0.82 per share. This marks the ninth consecutive year of dividend increases. Fiscal 2026 Outlook: • Adjusted Earnings per Diluted Share guidance range raised to $37.10 to $37.90, from the previous range of $36.90 to $37.70. • Fiscal 2026 Adjusted Earnings per Diluted Share guidance range indicates 12% to 15% growth compared to the prior year. Excluding fiscal 2025 net gains associated with McKesson Ventures' equity investments, the guidance range indicates 14% to 17% growth. • The Company does not forecast GAAP earnings per diluted share 1 . "McKesson had a standout quarter with momentum and growth across the enterprise," said Brian Tyler, chief executive officer. "We continue to execute against our strategy, delivering for our customers, partners, and patients. Our strong first quarter results included record revenue of $97.8 billion, representing 23% growth compared to the previous year. In addition, we closed the acquisitions of PRISM Vision Holdings and Core Ventures, further expanding our differentiated capabilities in Oncology and Specialty solutions. As a result of the strong first quarter performance and our confidence in the outlook for the remainder of the year, which includes the anno
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.